Abstract
Thyroid papillary carcinomas are characterized by RET/PTC rearrangements that cause the tyrosine kinase domain of the RET receptor to fuse with N-terminal sequences encoded by heterologous genes. This results in the aberrant expression of a ligand-independent and constitutively active RET kinase. We analysed actin reorganization induced by the RET/PTC1 oncogene in PC Cl 3 rat thyroid epithelial cells. Differently from oncogenes Src, Ras and Raf, RET/PTC1 caused actin filaments to form prominent stress fibers. Moreover, stress fibers were identified in human thyroid papillary carcinoma cell lines harboring RET/PTC1 rearrangements but not in thyroid carcinoma cells negative for RET/PTC rearrangements. RET/MEN 2A, a constitutively active but unrearranged membrane-bound RET oncoprotein, did not induce stress fibers in PC Cl 3 cells. Induction of stress fibers by RET/PTC1 was restricted to thyroid cells; it did not occur in NIH3T3 fibroblasts or MCF7 mammary cells. RET/PTC1-mediated stress fiber formation depended on Rho but not Rac small GTPase activity. In addition, inhibition of Rho, but not of Rac, caused apoptosis of RET/PTC1-expressing thyroid cells. We conclude that Rho is implicated in the actin reorganization and cell survival mediated by the chimeric RET/PTC1 oncogene in thyroid epithelial cells, both phenotypes being cell type- and oncogene type-specific.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abram CL, Courtneidge SA . 2000 Exp. Cell Res. 254: 1–13
Airaksinen MS, Titievsky A, Saarma M . 1999 Mol. Cell Neurosci. 13: 313–325
Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA . 1998 Oncogene 17: 1079–1087
Arighi E, Alberti L, Torriti F, Ghizzoni S, Rizzetti MG, Pelicci G, Pasini B, Bongarzone I, Piutti C, Pierotti MA, Borrello MG . 1997 Oncogene 14: 773–782
Asai N, Murakami H, Iwashita T, Takahashi M . 1996 J. Biol. Chem. 271: 17644–17649
Bar-Sagi D, Hall A . 2000 Cell 103: 227–238
Barone MV, Courtneidge SA . 1995 Nature 378: 509–512
Besset V, Scott RP, Ibanez CF . 2000 J. Biol. Chem. 275: 39159–39166
Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, Radice MT, Pierotti MA . 1996 Mol. Cell Biol. 16: 2151–2163
Cerione RA, Zheng Y . 1996 Curr. Opin. Cell Biol. 8: 216–222
Chiariello M, Visconti R, Carlomagno F, Melillo RM, Bucci C, de Franciscis V, Fox GM, Jing S, Coso OA, Gutkind JS, Fusco A, Santoro M . 1998 Oncogene 16: 2435–2445
Clark EA, Golub TR, Lander ES, Hynes RO . 2000 Nature 406: 532–535
Costello PS, Cleverley SC, Galandrini R, Henning SW, Cantrell DA . 2000 J. Exp. Med. 192: 77–85
De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, Billaud M, Fusco A, Tsichlis PN, Santoro M . 2000 Cancer Res. 60: 3727–3731
Durick K, Gill GN, Taylor SS . 1998 Mol. Cell Biol. 18: 2298–2308
Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP . 1993 J. Clin. Invest. 91: 179–184
Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M, Vecchio G . 1987 Mol. Cell Biol. 7: 3365–3370
Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G . 1990 Cell 60: 557–563
Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, Kurokawa K, Murakumo Y, Imai T, Funahashi H, Nakao A, Takahashi M . 2000 Oncogene 19: 4469–4475
Ishizaka Y, Ushijima T, Sugimura T, Nagao M . 1990 Biochem. Biophys. Res. Commun. 168: 402–408
Jhiang SM . 2000 Oncogene 19: 5590–5597
Kjoller L, Hall A . 1999 Exp. Cell Res. 253: 166–179
Kozma R, Sarner S, Ahmed S, Lim L . 1997 Mol. Cell Biol. 17: 1201–1211
Lorenzo MJ, Gish GD, Houghton C, Stonehouse TJ, Pawson T, Ponder BA, Smith DP . 1997 Oncogene 14: 763–771
Melillo RM, Barone MV, Lupoli G, Cirafici AM, Carlomagno F, Visconti R, Matoskova B, Di Fiore PP, Vecchio G, Fusco A, Santoro M . 1999 Cancer Res. 59: 1120–1126
Melillo RM, Carlomagno F, De Vita G, Formisano P, Vecchio G, Fusco A, Billaud M, Santoro M . 2001a Oncogene 20: 209–218
Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I . 2001b Mol. Cell Biol. 21: 4177–4187
Moorman JP, Luu D, Wickham J, Bobak DA, Hahn CS . 1999 Oncogene 18: 47–57
Nobes CD, Hall A . 1995 Biochem. Soc. Trans. 23: 456–459
Pandey A, Liu X, Dixon JE, Di Fiore PP, Dixit VM . 1996 J. Biol. Chem. 271: 10607–10610
Ponder BA . 1999 Cancer Res. 59: 1736–1741
Ridley AJ, Hall A . 1992 Cell 70: 389–399
Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A . 1992 Cell 70: 401–410
Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J . 1997 Cell 89: 457–467
Roger PP, Rickaert F, Huez G, Authelet M, Hofmann F, Dumont JE . 1988 FEBS Lett. 232: 409–413
Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, Mineo A, Fenzi G, Vecchio G, Fusco A, Santoro M . 2000 J. Clin. Endocrinol. Metab. 85: 3898–3907
Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP . 1995a Science 267: 381–383
Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G . 1995b Eur. J. Endocrinol. 133: 513–522
Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G, Fusco A . 1993 Cell Growth Differ. 4: 77–84
Schlumberger MJ . 1998 N. Engl. J. Med. 338: 297–306
Scita G, Nordstrom J, Carbone R, Tenca P, Giardina G, Gutkind S, Bjarnegard M, Betsholtz C, Di Fiore PP . 1999 Nature 401: 290–293
Scita G, Tenca P, Frittoli E, Tocchetti A, Innocenti M, Giardina G, Di Fiore PP . 2000 EMBO J. 19: 2393–2398
Segouffin-Cariou C, Billaud M . 2000 J. Biol. Chem. 275: 3568–3576
Van Aelst L, D'Souza-Schorey C . 1997 Genes Dev. 11: 2295–2322
Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A . 1995 Oncogene 11: 1207–1210
Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ . 1998 Oncogene 17: 1415–1438
Acknowledgements
We gratefully acknowledge JA Fagin for the human thyroid cell lines, J Downward for the Rho/Rac constructs and purified proteins, F Basolo for the FB2 cells and D Salvatore for phosphorylation-specific anti-RET antibodies. We are grateful to JA Gilder for editing the text. This study was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC), by the EC grant FIS5 1999 00032 and by the Progetto Biotecnologie ‘5%’ of the Consiglio Nazionale delle Ricerche (CNR). MV Barone was recipient of a scholarship of the Italian Foundation for Cancer Research (FIRC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barone, M., Sepe, L., Melillo, R. et al. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. Oncogene 20, 6973–6982 (2001). https://doi.org/10.1038/sj.onc.1204886
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204886
Keywords
This article is cited by
-
The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells
Scientific Reports (2015)
-
CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells
Cell Death & Disease (2014)
-
Influence of RET/PTC1 and RET/PTC3 oncoproteins in radiation-induced papillary thyroid carcinomas on amounts of cytoskeletal protein species
Amino Acids (2011)
-
The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation
Oncogene (2004)
-
Rho GTPases in human carcinogenesis: a tale of excess
Revista de Oncología (2003)